Global Congestive Heart Failure (CHF) Treatment Devices market is valued at 11 Billion US$ in 2018 is expected to reach 17.2 Billion US$ by the end of 2025, growing at a CAGR of 5.7% during 2019-2025 | Industry Leaders Covered | Abiomed, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Jarvik Heart, LivaNova PLC, Medtronic, ReliantHeart, St. Jude Medical|

Global Congestive Heart Failure (CHF) Treatment Devices market is valued at 11 Billion US$ in 2018 is expected to reach 17.2 Billion US$ by the end of 2025, growing at a CAGR of 5.7% during 2019-2025 | Industry Leaders Covered | Abiomed, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Jarvik Heart, LivaNova PLC, Medtronic, ReliantHeart, St. Jude Medical|

Press Release

Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.

The global Congestive Heart Failure (CHF) Treatment Devices market is valued at 11000 million US$ in 2018 is expected to reach 17200 million US$ by the end of 2025, growing at a CAGR of 5.7% during 2019-2025.
This report focuses on Congestive Heart Failure (CHF) Treatment Devices volume and value at global level, regional level and company level. From a global perspective, this report represents overall Congestive Heart Failure (CHF) Treatment Devices market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The report includes an in-depth analysis of the competitive landscape of this business vertical, constituting manufacturers like:
Abiomed
Berlin Heart GmbH
Biotronik SE & Co. KG
Boston Scientific Corporation
HeartWare International
Jarvik Heart
LivaNova PLC
Medtronic
ReliantHeart
St. Jude Medical

Market Segment by Regions includes:
North America
Europe
China
Japan

Products Segmentation, this report displays the production, revenue, price, market share, and growth rate of each type as below:
Cardiac Resynchronization Therapy (CRT)
Implantable Cardioverter Defibrillators (ICDs)

By Industrial Application, the market can be split into:
Left Ventricular Assist Device (LVAD)
Right Ventricular Assist Device (RVAD)
Biventricular Assist Device (BIVAD)

Market Segment by Regions includes:

  • North America (the USA, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America
  • Middle East and Africa.

Browse contents of Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2019

Contacts

Trusted Business Insights
Joseph Anthony Jones
Senior Media & Marketing Executive
US: +1 646 568 9797
UK: +44 330 808 0580

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,